Maxim analyst Allen Klee downgraded Marpai to Hold from Buy. The company’s Q3 results exceeded estimates, but the risk of dilution from its upcoming capital needs and the recent management changes balances its attractive technology and market opportunity, the analyst tells investors in a research note. The firm further cites the new management team having suspended guidance, with a call scheduled on 11/29 to discuss the strategic vision and initiatives in place.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRAI: